Equities Analysts Issue Forecasts for BrainsWay Q1 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – Equities research analysts at HC Wainwright decreased their Q1 2025 EPS estimates for BrainsWay in a research note issued on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.03 per share for the quarter, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at $0.24 EPS.

BrainsWay Price Performance

NASDAQ BWAY opened at $10.21 on Friday. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. The firm’s 50-day moving average is $10.26 and its two-hundred day moving average is $9.61. BrainsWay has a 12 month low of $4.61 and a 12 month high of $11.79.

Institutional Trading of BrainsWay

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP increased its stake in BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after purchasing an additional 1,786 shares during the period. Rhumbline Advisers increased its stake in BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the period. Cubist Systematic Strategies LLC increased its stake in BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares during the period. Lazard Asset Management LLC purchased a new stake in BrainsWay during the fourth quarter worth about $44,000. Finally, JPMorgan Chase & Co. increased its stake in BrainsWay by 61.9% during the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after purchasing an additional 9,149 shares during the period. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.